Business Context and Reporting Period
Company: MiMedx Group, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: December 30, 2014
Period Covered: Fourth quarter and full-year 2014 financial performance.
Key Financial Metrics
This filing serves as a notification of results and does not contain specific revenue, profit, cash flow, margin, debt, or liquidity figures. The detailed financial metrics are contained in the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in this text.
Material Changes and Corporate Actions
- Share Repurchase Program Extension: The Board of Directors extended the existing share repurchase program, originally authorized on May 12, 2014, through December 31, 2015.
- Program Status: The total authorization remains at $10 million. As of December 31, 2014, $4,416,322 remained available for repurchases.
- Future Purchases: The timing and amount of additional repurchases depend on stock price, market conditions, and regulatory requirements. The Company reserves the right to initiate, suspend, or discontinue purchases at any time.
Guidance, Outlook, and Management Commentary
Conference Call: The Company scheduled a live conference call for shareholders on January 2, 2015, at 10:30 am EST to discuss recent events and financial performance. A replay was made available on the Company's website.
Disclosure Status: Information regarding the results of operations is considered "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated December 30, 2014) for specific Q4 and full-year 2014 revenue, net income, and cash flow figures.
- Verify the remaining balance of the share repurchase program ($4,416,322) against subsequent trading activity.
- Confirm the terms of the extended repurchase program through December 31, 2015.
- Access the January 2, 2015, conference call replay for management's qualitative commentary on the reported results.